Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Leukemia, Lymphocytic, Chronic, B-Cell 4Myelodysplastic Syndromes 3Leukemia, Myeloid, Acute 3Primary Myelofibrosis 2Ovarian Neoplasms 2Myeloproliferative Disorders 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hodgkin Disease 2Triple Negative Breast Neoplasms 1Solid Tumor 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Biphenotypic, Acute 1Kidney Neoplasms 1Glioma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

pembrolizumab 141Nivolumab 117Ipilimumab 69Cyclophosphamide 34Specimen Handling 30Magnetic Resonance Spectroscopy 28trametinib 23fludarabine 22binimetinib 22Interleukin-2 21dabrafenib 19relatlimab 17encorafenib 17Biopsy 17aldesleukin 16CTLA-4 Antigen 16fludarabine phosphate 15cemiplimab 15atezolizumab 15Radiosurgery 15Opdualag 14Radiotherapy 11lifileucel 10lenvatinib 10Blood Specimen Collection 10spartalizumab 8Paclitaxel 8Cisplatin 8Bevacizumab 8cobimetinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Blood Component Removal × 1 year × Clear all
NCT03325101 2025-06-12

Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma

Mayo Clinic

Phase 1/2 Terminated
7 enrolled 11 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡